Share on StockTwits
 

Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) was the target of unusually large options trading activity on Tuesday. Traders bought 36,694 call options on the company, StockRatingsNetwork.com reports. This is an increase of 374% compared to the typical daily volume of 7,743 call options.

TEVA has been the subject of a number of recent research reports. Analysts at RBC Capital initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Monday, January 6th. They set a “sector perform” rating and a $39.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Monday, December 16th. They now have a $42.00 price target on the stock. Finally, analysts at Susquehanna upgraded shares of Teva Pharmaceutical Industries Ltd from a “neutral” rating to a “positive” rating in a research note to investors on Wednesday, November 20th. They now have a $50.00 price target on the stock, up previously from $43.00. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. Teva Pharmaceutical Industries Ltd has an average rating of “Hold” and an average target price of $44.08.

Shares of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) opened at 44.21 on Wednesday. Teva Pharmaceutical Industries Ltd has a 52-week low of $36.26 and a 52-week high of $45.12. The stock has a 50-day moving average of $40.35 and a 200-day moving average of $39.33. The company has a market cap of $37.357 billion and a price-to-earnings ratio of 29.40.

Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last announced its earnings results on Thursday, October 31st. The company reported $1.27 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.26 by $0.01. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $5.00 billion. During the same quarter last year, the company posted $1.28 earnings per share. Teva Pharmaceutical Industries Ltd’s revenue was up 1.7% compared to the same quarter last year. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post $4.99 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is a global pharmaceutical and drug company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.